title: How should we handle decreased efficacy caused by DDI on transporters for drug absorption and target-tissue distribution, but not associated with toxicity?
authors.affiliation: Faculty of Pharmaceutical Sciences, Kanazawa University.
authors.forename: Ikumi
authors.initials: I
authors.lastname: Tamai
mesh_terms: D001628:Beverages / Q000009:adverse effects; D004347:Drug Interactions; D005638:Fruit / Q000009:adverse effects; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects*; D027361:Organic Anion Transporters / Q000187:drug effects / Q000378:metabolism; D016593:Terfenadine / Q000031:analogs & derivatives / Q000378:metabolism; D014018:Tissue Distribution / Q000187:drug effects
chemical_list: D027361:Organic Anion Transporters; C450859:SLCO2B1 protein, human; D016593:Terfenadine; C093230:fexofenadine